MedPath

Buprenorphine Pharmacology Related to Addiction Treatment - 18

Phase 2
Completed
Conditions
Opioid-Related Disorders
Registration Number
NCT00000236
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Brief Summary

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Opioid agonist effects
Drug use
Opiate withdrawal
Psychological changes in: pupil diameter, blood pressure, heart rate, respiration
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Treatment Research Center

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath